Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from ArcticZymes Technologies ASA ( (DE:B4V) ).
ArcticZymes Technologies reported a strong finish to 2025, with fourth-quarter sales revenue rising 39% year-on-year to NOK 34.1 million and EBITDA more than tripling as improved product mix and cost discipline boosted margins. For the full year, the company returned to growth with sales up 8% to NOK 112.6 million and EBITDA more than doubling to NOK 12 million, supported by a robust balance sheet featuring substantial cash reserves and no interest-bearing debt.
Growth was led by the Biomanufacturing segment, where revenues rose 23% for the year and GMP-grade product sales more than doubled in the fourth quarter, while Molecular Tools rebounded strongly in Q4 despite a modest full-year decline. Management signalled that the strengthened financial position and accelerating uptake among CDMOs and key accounts will underpin further expansion in 2026, as ArcticZymes scales biomanufacturing, broadens enzyme applications including metagenomics, and builds out its RNA enzyme portfolio.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies ASA is a Norwegian life sciences company that develops, manufactures and commercialises novel recombinant enzymes used in molecular research, in vitro diagnostics and biomanufacturing. Listed on the Oslo Stock Exchange and headquartered in Tromsø’s SIVA Science Park, the company serves global customers with a patented enzyme portfolio that underpins applications from CDMO bioprocessing to advanced molecular tools.
Average Trading Volume: 58,542
Current Market Cap: NOK1.1B
Find detailed analytics on B4V stock on TipRanks’ Stock Analysis page.